Completed PHASE1 NCT01787747

Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers

A Phase 1, Single-center, Randomized, Double-blind, Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Doses of AVP-786 (Deuterated Dextromethorphan) in Healthy Volunteers

Sponsor: Avanir Pharmaceuticals

Conditions Healthy

Interventions AVP-786 Dose 1 AVP-786 Dose 1/Q Dose 1 AVP-786 Dose 1/Q Dose 2 AVP-786 Dose 2 AVP-786 Dose 2/Q Dose 2 AVP-923

Updated 5 times since 2017 Last updated: Jun 24, 2014 Started: Oct 31, 2012 Primary completion: Feb 28, 2013 Completion: Feb 28, 2013

Listed as NCT01787747, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Avanir Pharmaceuticals, it has been updated 5 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Avanir Pharmaceuticals

Data source: Avanir Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Adelaide, Australia